Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talquetamab - Genmab/Janssen Research & Development

X
Drug Profile

Talquetamab - Genmab/Janssen Research & Development

Alternative Names: GPRC5D/CD3-duobody-antibody-JNJ-64407564; JNJ 64407564; JNJ-7564; TALVEY

Latest Information Update: 09 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Janssen Research & Development
  • Developer Janssen Research & Development
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Multiple myeloma
  • Phase II Smoldering multiple myeloma

Most Recent Events

  • 04 Apr 2024 University of California and Janssen Research & Development plans a phase Ib trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT06348108)
  • 29 Jan 2024 Janssen Research & Development initiates the phase III MonumenTAL-6 trial in Multiple myeloma (Combination therapy) in Australia and South Korea (SC) (NCT06208150)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Canada (SC, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top